Diabetes

Latest News


FDA has warned that the drug class dipeptidyl peptidase-4 (DPP-4) inhibitors may cause joint pain that can be severe and disabling. In a statement, the FDA said said it had issued a "warning and precaution" to all labels in this drug class.

The top stories in managed care include results for patients with type 2 diabetes who were treated with high-dose liraglutide, challenges facing Medicaid managed care, and the rising popularity of doula services.